Major investment for The Royal Clinical Brain Research Centre to understand mental illness, addiction
The Royal Ottawa Mental Health Centre unveiled one of the world's most advanced brain imaging technology to better understand mental illness and addiction. (Kimberley Fowler/ CTV News Ottawa)
On Thursday, The Royal Ottawa Mental Health Centre unveiled one of the world's most advanced brain imaging technology to better understand mental illness and addiction. It's a state-of-the-art neuroimaging platform, promising to put Canada at the forefront of global brain research.
In partnership with Brain Canada, The Royal is announcing a $1.9 million grant to launch a first-of-its-kind brain imaging platform in Canada, giving researchers a new look inside the brain and creating the opportunity to transform mental health research.
Brain Canada president and CEO, Dr. Viviane Poupon says: 'I'm a neuroscientist by training, so for me to see the future of neuroscience, the breakthroughs that are going to happen, and building capacity for the researchers, for me is always amazing.'
'We're super excited to get to continue to grow this facility,' said Katie Dinelle, The Royal's administrative director of the Clinical Brain Research Centre. 'It has been here since 2016, and this is a big 'next step' for us.'
The state-of-the-art neuroimaging platform allows researchers to scan the brain three ways at once. An MRI (Magnetic Resonance Imaging) provides detailed images of the brain, a PET (Positron Emission Tomography) acts a radioactive tracer to show brain activity and function, and an EEG (Electroencephalography) to measure electrical activity in the brain in real time.
Only three teams in the world use this brain scanning technology for an unprecedented look at how the brain works.
'The idea with this grant is to combine all three of those imaging modalities to give us a very whole picture of the brain,' said Dinelle.
Dr. Georg Northoff, senior scientist at The Royal and Psychiatry professor at the University of Ottawa says 'with depression you're extremely sad, you have anxiety disorders, also your sense of self can be very different, or you see yourself only as negative. So, understanding the basic mental brain-mind connection for basic mental features also implies that we can learn something from mental disorders.'
The multi-modal imaging will also help researchers improve diagnostics and personalized treatments for mental health patients.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
44 minutes ago
- Globe and Mail
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , June 20, 2025 /CNW/ -- USA News Group News Commentary – The costs of cancer drugs is skyrocketing, according to a recent report from Bloomberg. Analysts at Nova One Advisor estimate that the global oncology drugs market will grow at a 7.4% CAGR through to US$366.24 billion by 2034. Help doesn't appear to be coming from the public sector, as reports state that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For investors to note, plenty of oncology innovators have provided recent developments, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Immuneering Corporation (NASDAQ: IMRX), GRAIL, Inc. (NASDAQ: GRAL), Intensity Therapeutics, Inc. (NASDAQ: INTS), and Relay Therapeutics, Inc. (NASDAQ: RLAY). The global oncology market is expected to see strong growth over the next decade, with ResearchAndMarkets forecasting it to reach US$866.1 billion by 2034 at a 10.8% CAGR. A separate estimate from Vision Research Reports projects the market will surpass US$903.81 billion by the same year, growing at a 10.9% CAGR. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has entered a new phase of leadership with the appointment of Jared Kelly as Chief Executive Officer and member of the Board. Kelly brings a background in high-stakes biotech transactions and strategic immuno-oncology development, positioning him to guide the company through its next stage of clinical and business evolution. Before joining Oncolytics, Kelly served as General Counsel at Ambrx Biopharma, where he played a key role in its $2 billion acquisition by Johnson & Johnson. His earlier work includes advising life sciences firms on licensing, partnerships, and M&A while at Kirkland & Ellis LLP and Lowenstein Sandler LLP. Now leading Oncolytics, he steps into a company advancing pelareorep, a virus-based immunotherapeutic designed to work synergistically with checkpoint inhibitors and other agents across a range of solid and blood cancers. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients," said Jared Kelly , CEO of Oncolytics Biotech. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders." Kelly's appointment signals a clear strategic focus: advancing pelareorep toward key late-stage milestones through a capital-conscious approach that remains open to strategic collaboration. Pelareorep currently holds FDA Fast Track designation for both metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) —a rare dual recognition that underscores its regulatory momentum. Across multiple studies, the virus-based therapy has demonstrated consistent immune activation, broad combinability with checkpoint inhibitors and chemotherapies, and encouraging response rates in challenging cancer types. In mPDAC, pelareorep has achieved over 60% objective response rates in tumor-evaluable patients across Phase 1 and 2 trials—more than double what's typically seen in historical benchmarks. Separate analyses also reported two-year survival rates four to six times higher than control arms or prior studies. In HR+/HER2- mBC, two randomized Phase 2 trials (IND-213 and BRACELET-1) showed survival benefits supportive of further investigation. Meanwhile, a Phase 2 cohort in anal cancer pairing pelareorep with a checkpoint inhibitor reported partial or complete responses in nearly half of evaluable patients—substantially higher than historical norms for monotherapy in this setting. "Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date," said Wayne Pisano , Chair of the Board and outgoing Interim CEO of Oncolytics. "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors." Kelly's compensation package includes equity grants and milestone-linked incentives tied to future financings and potential strategic transactions—aligning leadership priorities with long-term shareholder interests. The structure signals a commitment to advancing both clinical and corporate goals while preserving balance sheet discipline and maintaining appeal for potential partners. With multiple cohorts progressing in the GOBLET study—including those in pancreatic and anal cancer supported by external funding and regulatory engagement— Oncolytics is positioned to move forward with a combination of scientific momentum, financial agility, and renewed strategic focus. In other recent industry developments and happenings in the market include: Immuneering Corporation (NASDAQ: IMRX) reported positive Phase 2a data for atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. At six months, the study showed 94% overall survival and 72% progression-free survival in 34 patients, with no median OS or PFS reached yet. "These exceptional data demonstrate the potential of atebimetinib plus mGnP to dramatically extend the lives of patients with advanced pancreatic cancer," said Ben Zeskind , Ph.D., Co-founder and CEO of Immuneering. "Our ultimate goal is to help cancer patients outlive their disease, and today's announcement represents an important milestone on that journey." The combination also demonstrated a 39% overall response rate, an 81% disease control rate, and a notably favorable tolerability profile. Many patients experienced deep, durable tumor regressions, including lesions rendered undetectable. The regimen was well tolerated, with an adverse event profile suggesting potential best-in-class positioning among MEK inhibitors. GRAIL, Inc. (NASDAQ: GRAL), recently announced strong top-line results from the PATHFINDER 2 registrational study evaluating its Galleri® multi-cancer early detection test in over 25,000 adults. "We are delighted to see very encouraging performance of the Galleri MCED test as a cancer screening tool in broad intended use populations of asymptomatic adults over 50 years of age in both the PATHFINDER 2 study and the NHS-Galleri trial's prevalent screening round," said Josh Ofman , MD, MSHS, President at GRAIL. "We would like to extend our sincere gratitude to all of the participants and investigators in both of these pivotal studies, who are collectively helping to realize the potential of this groundbreaking technology for population-scale multi-cancer early detection and move the field forward." The study showed a substantially higher positive predictive value (PPV) compared to the original PATHFINDER trial, with consistent specificity and cancer signal origin accuracy, and no serious safety concerns reported. GRAIL plans to submit these results to the FDA as part of its ongoing premarket approval process under Breakthrough Device Designation. Intensity Therapeutics, Inc. (NASDAQ: INTS) announced that the first patients in its ongoing Phase 2 INVINCIBLE-4 trial achieved high levels of tumor necrosis within eight days of receiving two doses of INT230-6, before starting standard-of-care immunochemotherapy for triple-negative breast cancer (TNBC). "We are excited to see that INT230-6 is achieving meaningful levels of necrosis in patients with evidence of immune activation," said Lewis H. Bender , President and CEO of Intensity. "TNBC patients risk their lives to achieve a pCR, and about forty percent fail to achieve the desired result." MRI scans showed substantial tumor destruction and inflammation, suggesting immune activation following direct intratumoral injection. The randomized study compares INT230-6 followed by standard treatment versus standard treatment alone, with pathological complete response (pCR) as the primary endpoint. Relay Therapeutics, Inc. (NASDAQ: RLAY) reported updated interim data from its Phase 1/2 study of RLY-2608 plus fulvestrant, showing a median progression-free survival (PFS) of 11.0 months in second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. "We are encouraged by the consistency of these updated RLY-2608 + fulvestrant data, which continue to show the potential benefit of a mutant-selective PI3Kα inhibitor for improving both the tolerability profile and progression free survival compared to standard of care," said Don Bergstrom , M.D., Ph.D., President of R&D at Relay Therapeutics. "We look forward to starting the first mutant-selective PI3Kα Phase 3 trial, ReDiscover-2, in the middle of this year." Among patients at the recommended Phase 3 dose, the clinical benefit rate reached 67%, and 39% had confirmed partial responses, with notably higher response rates in those with kinase mutations. The combination maintained a favorable tolerability profile, with low rates of high-grade adverse events and minimal treatment discontinuations. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
National Post
2 hours ago
- National Post
How does a rockslide happen? 'The mountain that moves' was Canada's deadliest
A large rockslide in Banff National Park left up to 15 hikers injured Thursday, leading to one potential death and raising a series of questions about how and why the disaster occurred. Article content With officials still working on rescue and treatment of survivors, it will be some time until an investigation concludes why the rockslide happened. But a look at published research and archive news articles on rockslides provides some general information about the dangerous occurrences. Article content Article content Article content Article content A rockslide happens when a large chunk of rock detaches itself from the mountain where it sits and begins sliding down the slope. Why does this occur? Well, natural erosion or seismic activity can cause a rockslide, as can heavy rainfalls. Human activity such as excavation, construction or mining can also lead to a rockslide. Article content As one chunk of rock begins its downward slide, it can quickly gain momentum and trigger massive amounts of other rock to also begin sliding, leading to devastating effects. notes a landslide or rockslide can occur 'when gravitational and other types of shear stresses within a slope exceed the shear strength (resistance to shearing) of the materials that form the slope.' Article content What's the difference between a landslide and a rockslide? Article content A landslide occurs when sediment or loose dirt disengages from a hill or mountain and begins moving downwards. A rockslide, however, means solid rocks are also being swept down a slope during a similar type of event. Rockslides are also incredibly fast-moving, as they tend to move down a flat surface of a mountain. Article content The most horrific rockslide in Canadian history occurred in 1903 when a huge slab of Turtle Mountain crashed down onto the town of Frank and Crowsnest Pass (about 250 kilometres southwest of Calgary). At least 72 known residents were killed in the natural disaster, as were an undetermined number of others visiting or passing through the area. Some historians thus put the death toll closer to 90. Article content An estimated 80 to 110 million tonnes of rock were involved in the deadly event that came to be known as Frank Slide. The rockslide only lasted about a minute and a half. Article content Newspaper clippings and archive stories from the rockslide describe the horrific results that led to the deaths of men, women and children. As those clippings note, information about the state of some of the victims was disturbing, but shed light on how powerful the rockslide was: 'The leg and hip of a man was found lying fifty yards from the Imperial Hotel.'
CTV News
2 hours ago
- CTV News
Providing public health care dollars to private clinics for surgeries resulting in health inequality: Union
A union says the plan by the Ford government to continue expanding hospital services to include more for-profit clinics will lead to a wider gap in health equit The head of CUPE's Ontario Council of Hospital Unions (OCHU) is on a cross-province tour with a senior researcher highlighting data compiled on impacts within health care. 'We believe if the public is more familiar with the details of this [government] policy it will lose popular support, and the government will have to reconsider it,' Michael Hurley, CUPE regional vice president in Ontario, said to media in Sudbury on Thursday. Michael Hurley of CUPE's Ontario Council of Hospital Unions discusses research in Sudbury on private clinic surgeries Michael Hurley of CUPE's Ontario Council of Hospital Unions discusses research in Sudbury on private clinic surgeries. June 19, 2025 (Angela Gemmill/CTV Northern Ontario 'So, I think we have to wear them down over time, to be honest with you.' Five years ago, the Conservative government approved plans to allow public health care dollars to go to private for-profit clinics to perform cataract surgeries, stating it would help reduce wait times. Last year, the Ministry of Health announced that private clinics could also perform hip and knee surgeries covered by the Ontario Health Insurance Plan (OHIP). The union said data from the Canadian Institute for Health Information shows that wait times have worsened since 2020. It's also concerned that gaps in health inequality will grow wider. 'Twenty per cent of the population, the wealthiest 20 per cent, actually saw a significant increase in cataract surgery access with the increased funding. Whereas every other demographic group -- the other four quintiles -- saw less access to care. Worst of all among the poorest among us,' said Doug Allan, a CUPE senior researcher. 'For example, we know in Sudbury that there is significant inequality in terms of access to cataract surgery based on your income and that level of marginalization in the community.' CUPE researcher Doug Allan CUPE researcher Doug Allan discusses research in Sudbury on private clinic surgeries. June 19, 2025 (Angela Gemmill/CTV Northern Ontario The union also said many of the private, for-profit clinics upsell or charge user fees. In fact, after hearing numerous complaints from her constituents in Nickel Belt who were charged add-on fees for extras during their surgeries, the NDP health critic, MPP France Gelinas, issued an open letter to Health Minister Sylvia Jones. Gelinas said many of the fees charged by private for-profit clinics are in violation of the Canada Health Act. France Gelinas France Gelinas, Ontario health critic and Nickel Belt MPP. June 19, 2025 (Angela Gemmill/CTV Northern Ontario She told CTV News that patients who are in need of cataract surgery are seniors on a fixed income who don't have an extra $600 to $1,200. 'The surgeon is about to put a laser to your eye and says to you that he prefers to use this [special lens]. You don't argue. You're not in a position to bargain, you just pay,' Gelinas said. 'If you are really rich, this is perfect. You will pay to be at the front of the line and you will get really good access. If you're like the rest of us, not very rich, the wait times will be longer in our public hospital.' In an email to CTV, News a Ministry of Health spokesperson said, 'Ontario is leading the county with some of shortest wait times for critical surgeries and procedures,' adding 32,000 people received 'publicly funded cataract surgery at community surgical and diagnostic centres' last year. 'Our government will continue to deliver more connected, convenient care in every corner of the province, always ensuring that people are accessing the care they need with their OHIP card, never their credit card,' a statement from the ministry reads. Statement from Ontario Ministry of Health on private clinic surgeries Statement from Ontario Ministry of Health on private clinic surgeries. June 19, 2025 (Angela Gemmill/CTV Northern Ontario The email also stated that Ontario has legislated provisions that prohibit a patient from being charged for an OHIP covered service.
